Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	179474-81-8
Formula :	C₁₈H₂₆ClN₃O₃
M.W :	367.87
SMILES Code :	O=C(C1=C(OCC2)C2=C(N)C(Cl)=C1)NC3CCN(CCCOC)CC3
Synonyms :	R-93877
MDL No. :	MFCD09837787
InChI Key :	ZPMNHBXQOOVQJL-UHFFFAOYSA-N
Pubchem ID :	3052762

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H302-H319-H372-H410
Precautionary Statements:	P501-P273-P260-P270-P264-P280-P391-P314-P337+P313-P305+P351+P338-P301+P312+P330
Class:	9
UN#:	3077
Packing Group:	Ⅲ

M2-type bone marrow-derived macrophages	20 ng/mL IL4	24 hours	To evaluate the effect of IL4 on BMDM polarization, results showed that IL4-treated BMDM expressed α7nAChR.	PMC6691854
CHO-K1 cells	5 pM to 1 nM	60 minutes	Evaluate the inhibitory effect of DLT on 5HT2AR	PMC5773938
Human colon circular muscle cells	1 μM		Prucalopride usually increased the amplitude of cholinergically mediated contractions evoked by EFS, with smaller increases in the amplitude of the after-contractions. In the presence of L-NAME, the excitatory actions of prucalopride on cholinergic function were sometimes less clear.	PMC3838700
Porcine right atrium	0.1 nM to 10 μM		To investigate the chronotropic effects of 5-HT4 receptor agonists on porcine right atrium. Results showed that all agonists produced chronotropic effects when administered cumulatively, without fading.	PMC1615862
Porcine left atrial pectinate muscles	0.1 nM to 10 μM	3 to 60 minutes	To investigate the inotropic and lusitropic effects of 5-HT4 receptor agonists on porcine left atrial pectinate muscles. Results showed that all agonists produced positive inotropic effects when administered noncumulatively, but only 5-HT produced positive inotropic effects when administered cumulatively. PDE inhibitor IBMX enhanced the inotropic effects of all agonists.	PMC1615862

Mice	Postoperative ileus (POI) model	Oral gavage	1 or 5 mg/kg	Single dose 1.5 hours before or 22.5 hours after surgery	To evaluate the effect of Prucalopride on postoperative ileus, results showed that preoperative administration reduced intestinal inflammation and improved intestinal transit, while postoperative administration was ineffective.	PMC6691854
Male C57BL/6j mice	Wild-type and APP/V717I transgenic mice	Subcutaneous injection	5 or 10 mg/kg	Single injection, mice were killed 90 min after the injection	To investigate the effect of 5-HT4 receptor agonists on sAPPα levels. Results showed that prucalopride significantly increased sAPPα levels in the hippocampus and cortex, and this increase was inhibited by the 5-HT4 receptor antagonist GR125487.	PMC2013878
Male C57BL/6J mice	DSS-induced colitis model	Oral	5 mg/kg	Once daily for 7 days	Restored small intestinal motility and attenuated colitis	PMC11127033
129S6/SvEv mice	Contextual fear conditioning model	Intraperitoneal injection	3 or 10 mg/kg	Single injection, behavioral tests conducted one week later	Prucalopride at 3 mg/kg attenuated learned fear and decreased stress-induced depressive-like behavior.	PMC6969048
C57BL/6 mice	MPTP-induced Parkinson’s disease model mice	Intraperitoneal injection	1.5 or 3 mg/kg	Administered 2 h before each training session, twice in total	Prucalopride prevented the facilitation of contextual fear extinction in PD mice at days 2 and 3 in a dose-dependent manner, but did not have any significant effect on contextual fear extinction in control mice.	PMC6862438
Rats	Postoperative ileus model	Intravenous injection	1 mg/kg and 5 mg/kg	Single dose one minute before the operation	To evaluate the effect of prucalopride on postoperative ileus. Results showed that prucalopride at 1 mg/kg significantly increased intestinal transit after laparotomy, but the effect was not significant at 5 mg/kg.	PMC1727718
Guinea pigs	Guinea pig isolated distal colon longitudinal muscle myenteric plexus (LMMP)	Oral	0.1 to 10 mg/kg	Single dose, observed for 6 hours	Evaluate the effect of Prucalopride on faecal pellet output in guinea pigs. Results showed Prucalopride was most effective at 3 mg/kg.	PMC5773938

{[proInfo.proName]}

CAS No.: 179474-81-8

{[proInfo.proName]}

CAS No.: 179474-81-8

Alternative Products

Product Details of Prucalopride

Safety of Prucalopride

Related Pathways of Prucalopride

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03610217	Scleroderma, Systemic ... More >> Sclerosis, Systemic Less <<	Not Applicable	Not yet recruiting	October 2021	Canada, Ontario ... More >> Saint Joseph's Health Care London Not yet recruiting London, Ontario, Canada, n6a 4v2 Contact: Janet E Pope, MD, MPH, FRCPSC 15196466332 Janet.Pope@sjhc.london.on.ca Contact: Andreu Fernandez-Codina 151964661023 doccodina@gmail.com Less <<
NCT02538367	Functional Constipation	Phase 1 Phase 2	Completed	-	Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of Less <<
NCT01902537	-		Completed	-	Korea, Republic of ... More >> Seoul, Korea, Republic of Less <<
NCT02425774	Postoperative Ileus	Phase 4	Recruiting	December 2017	Belgium ... More >> University hospitals Leuven Recruiting Leuven, Vlaams-Brabant, Belgium, 3000 Contact: Nathalie Stakenborg, MSc +32 16 342883 nathalie.stakenborg@med.kuleuven.be Contact: Kim Van Beek, MSc +32 16 341326 kim.vanbeek@med.kuleuven.be Principal Investigator: Guy Boeckxstaens, M.D. Less <<
NCT01655095	Quality of Bowel Preparation f... More >>or the Colon Capsule Colon Capsule Completion Rates Colon Capsule Polyp Detection Less <<	Phase 3	Completed	-	Canada, Ontario ... More >> Hotel Dieu Hospital Kingston, Ontario, Canada Less <<
NCT00793429	Healthy	Phase 1	Completed	-	-
NCT01870674	Healthy	Phase 1	Completed	-	Korea, Republic of ... More >> Inje Busan Paik hospital Busan, Korea, Republic of, 614-735 Less <<
NCT00485940	Constipation	Phase 3	Completed	-	-
NCT00627692	Constipation	Phase 2	Completed	-	-
NCT00577018	Constipation	Phase 3	Completed	-	-
NCT01070615	Chronic Constipation	PHASE3	COMPLETED	-	University Hospital Antwerp, E... More >>degem, 2650, Belgium Less <<
NCT01330381	Functional Constipation	Phase 3	Completed	-	Netherlands ... More >> Academisch Medisch Centrum Amsterdam, Netherlands, 1105 AZ Less <<
NCT01869751	Constipation		WITHDRAWN	2025-12-18	University Hospitals Leuven, L... More >>euven, Vlaams-Brabant, 3000, Belgium Less <<
NCT01330381	-		Completed	-	-
NCT00987844	Chronic Constipation	PHASE3	COMPLETED	-	Mayo Clinic, Rochester, Minnes... More >>ota, 55905, United States Less <<
NCT01036893	Healthy Volunteers	Phase 1	Completed	-	Germany ... More >> FOCUS GmbH Neuss, Germany, D-41460 Less <<
NCT00575614	Constipation	Phase 2	Completed	-	-
NCT01134185	Hepatic Impairment	Phase 1	Completed	-	Russian Federation ... More >> Moscow, Russian Federation Less <<
NCT00483886	Constipation	Phase 3	Completed	-	-
NCT00617513	Constipation	Phase 2	Completed	-	-
NCT01147926	Male Subjects With Chronic Con... More >>stipation Less <<	Phase 3	Completed	-	-
NCT00598338	Constipation	Phase 3	Completed	-	-
NCT02228616	Constipation	Phase 4	Completed	-	China ... More >> Beijing, China Bin Zhou, China Chongqing, China Hangzhou, China Nanjing, China Shanghai, China Tianjin, China Wuhan, China Zhengzhou, China Less <<
NCT01251822	Constipation	Phase 3	Completed	-	Romania ... More >> Pierrel Research Timisoara, Romania, RO-300244 Less <<
NCT01147926	-		Completed	-	-
NCT00631813	Constipation	Phase 2	Completed	-	-
NCT00596596	Constipation	Phase 2	Completed	-	-
NCT01707667	Chronic Constipation	Phase 4	Completed	-	United States, Oklahoma ... More >> Oklahoma Foundation for Digestive Research Oklahoma City, Oklahoma, United States Belgium UNIVERSITY OF LEUVEN, UNVERSITY HOSPITAL, Gasthuisberg Leuven, Belgium, 3000 United Kingdom Barts Health NHS Trust Whitechapel, London, United Kingdom Less <<
NCT01424228	Constipation	Phase 4	Completed	-	-
NCT01707667	-		Completed	-	-
NCT00488137	Constipation	Phase 3	Completed	-	-
NCT00576511	Chronic Constipation	Phase 2	Completed	-	-
NCT01424228	-		Completed	-	-
NCT00793247	Chronic Intestinal Pseudo-Obst... More >>ruction Less <<	Phase 2	Completed	-	United Kingdom ... More >> Northwick Park Hospital London, United Kingdom Less <<
NCT02031081	Gastroparesis ... More >> Diabetes Mellitus Less <<	Phase 2 Phase 3	Completed	-	Canada, Alberta ... More >> University of Calgary Calgary, Alberta, Canada, T2N 4Z6 Less <<
NCT03244553	Ineffective Esophageal Motilit... More >>y\|Dysphagia Less <<	PHASE2	COMPLETED	2019-12-02	University of Calgary, Calgary... More >>, Alberta, T2N 1N4, Canada Less <<
NCT01807000	Healthy	Phase 1	Completed	-	United States, Wisconsin ... More >> Covance Global Clinical Research Unit Inc. Madison, Wisconsin, United States, 53704 Less <<
NCT01864915	Bowel Cleansing ... More >> Colon Capsule Completion Times Less <<	Phase 3	Completed	-	Canada, Ontario ... More >> Hotel Dieu Hospital Kingston, Ontario, Canada, K7L 5V7 Less <<
NCT02047045	Constipation	Not Applicable	Completed	-	-
NCT00488215	Constipation	Phase 1	Completed	-	-
NCT01807000	-		Completed	-	-
NCT03279341	Chronic Constipation	Phase 4	Completed	-	Belgium ... More >> TARGID Leuven, Belgium, 3000 Less <<
NCT02781493	Prucalopride Plus Polyethylene... More >> Glycol in Bowel Preparation for Colonoscopyp Less <<	Phase 4	Unknown	March 2017	China, Shandong ... More >> Department of Gastroenterology, Qilu Hospital, Shandong University Not yet recruiting Jinan, Shandong, China, 250012 Contact: Yanqing Li, MD, PhD 86-0531-82169236 liyanqing@sdu.edu.cn Less <<
NCT01117051	Non-cancer Pain ... More >> Opioid Induced Constipation Less <<	Phase 3	Terminated(The study was stopp... More >>ed by the sponsor based on a non-safety related business priority decision) Less <<	-	Belgium ... More >> Leuven, Belgium Less <<
NCT00903747	Constipation	Phase 1	Completed	-	-
NCT01117051	-		Terminated(The study was stopp... More >>ed by the sponsor based on a non-safety related business priority decision) Less <<	-	-
NCT03676374	GERD	Phase 4	Recruiting	April 2021	Belgium ... More >> UZ Leuven Recruiting Leuven, Belgium, 3000 Contact: Hannelore Geysen +32 (0)16 324921 hannelore.geysen@kuleuven.be Less <<
NCT01674166	Constipation	Phase 1	Completed	-	-
NCT02947269	Postoperative Ileus ... More >> Colorectal Surgery Postoperative Complications Less <<	Phase 3	Recruiting	February 2019	New Zealand ... More >> University of Auckland Recruiting Auckland, New Zealand, 1023 Contact: Ian Bissett, MD, FRACS +649 3737599 ext 89821 i.bissett@auckland.ac.nz Less <<
NCT01692132	Chronic Constipation		WITHDRAWN	2025-12-14	Makati City, Philippines\|Manil... More >>a, Philippines\|Marikina City, Philippines\|Muntinlupa, Philippines\|Quezon City, Philippines\|San Juan, Philippines\|Taguig, Philippines Less <<
NCT02510976	Gastroparesis	Phase 4	Unknown	-	Belgium ... More >> University Hospitals Recruiting Leuven, Vlaanderen, Belgium, 3000 Contact: Jan Tack, M.D., Ph.D. +3216344225 jan.tack@med.kuleuven.be Principal Investigator: Jan Tack, M.D., Ph.D. Less <<
NCT02004652	Postoperative Ileus	Phase 2	Completed	-	China, Jiangsu ... More >> Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University Nanjing, Jiangsu, China, 210002 Less <<
NCT03572790	Molecular Mechanisms of Pharma... More >>cological Action Depression Depressive Disorder Mood Disorders Mental Disorders Antidepressive Agents Cognition Less <<	Not Applicable	Not yet recruiting	March 2020	United Kingdom ... More >> University of Oxford Not yet recruiting Oxford, United Kingdom, OX3 7JX Less <<
NCT01116206	Constipation	Phase 3	Completed	-	Australia ... More >> Adelaide, Australia Box Hill, Australia Kingswood, Australia Kogarah, Australia Newcastle, Australia Parkville, Australia Prahran, Australia Sydney, Australia China Beijing, China Chongqing, China Guangzhou, China Hangzhou, China Hefei, China Jinan, China Nanjing, China Shanghai, China Wuhan, China Xian, China Korea, Republic of Busan, Korea, Republic of Dae-Gu, Korea, Republic of Deajun, Korea, Republic of Gwangju-Si, Korea, Republic of Iksan, Korea, Republic of Seoul, Korea, Republic of Taiwan Taipei, Taiwan Thailand Bamgkok, Thailand Bangkok, Thailand Less <<
NCT01674192	Constipation	Phase 1	Completed	-	-
NCT01670669	Constipation	Phase 1	Completed	-	-
NCT00487422	Constipation	Phase 3	Completed	-	-
NCT02806206	Gastrointestinal Hemorrhage ... More >> Crohn Disease Celiac Disease Intestinal Diseases Inflammatory Bowel Diseases Less <<	Phase 4	Unknown	May 2017	Canada, British Columbia ... More >> Vancouver General Hospital Vancouver, British Columbia, Canada, V5Z 1M9 Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed